A handful of rapid 2019-nCoV assays are in the works which could help triage patients more effectively and avoid unnecessary quarantines.
The company said it has started the CE mark approval process of commissioned high-risk HPV genotyping assays and expects to certify them this year.
The firms noted that QuantuMDx’s Capture-XT technology will enable downstream drug-susceptibility analysis, PCR, NGS, and, with this collaboration, nanopore detection.
FIND also announced support for projects from Axxin and DNC Dx for point-of-care detection of sexually transmitted infections.
The British molecular diagnostics firm recently completely a redesign of its point-of-care system, called Q-POC, and is planning to seek a CE-IVD mark for the device later this year.
QuantuMDx and Molbio Diagnostics said this week they have signed a memorandum of understanding to work jointly in infectious disease diagnostics.
The firm also announced the appointment of new board members as it heads toward commercialization of a portable MDx platform.
The test will be developed in Global Good labs and ported onto QuantuMDx's handheld molecular platform.
The funding will be used to further develop a 20-minute tuberculosis detection assay and drug susceptibility test using the firm's handheld Q-POC microfluidic PCR system.
QuantuMDx says its low-cost, handheld device will be able to quickly diagnose patients, as the Guardian reports.
At the Lancet, more than two dozen public health researchers condemn the conspiracy theories that have emerged surrounding the source of the COVID-19 outbreak.
The Washington Post reports that Philip Leder, who helped uncover how DNA codes for proteins and studied the role of genes in cancer, has died.
Researchers from Trinity College Dublin and the University of Pittsburgh look into how often de novo genes arise and how important they may be.
In Nucleic Acids Research this week: pipeline for genotyping Alu retrotransposon mobile element insertions, previously undocumented non-coding RNAs, and more.